US Patent

US9193701 — Pyruvate kinase activators for use in therapy

Method of Use · Assigned to Agios Pharmaceuticals Inc · Expires 2032-10-26 · 6y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for using compounds that activate pyruvate kinase.

USPTO Abstract

Described herein are methods for using compounds that activate pyruvate kinase.

Drugs covered by this patent

mitapivat-sulfate (MITAPIVAT SULFATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3319`	—	mitapivat-sulfate
`U-3319`	—	mitapivat-sulfate
`U-3319`	—	mitapivat-sulfate
`U-4393`	—	mitapivat-sulfate

Patent Metadata

Patent number: US9193701
Jurisdiction: US
Classification: Method of Use
Expires: 2032-10-26
Drug substance claim: No
Drug product claim: No
Assignee: Agios Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.